Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2023 Filed Sep 6, 2023 17:00 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Tax withholdingBio-Rad A Common Stock | 240 | $394.60 | $94,704.00 |
DisclosureSEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,966.212 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 17:00 UTC |
Daskal IlanEVP, Chief Financial Officer
|
Exercise / conversionBio-Rad A Common Stock | 694 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,206.212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 30 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · derivative · entry 13 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62 Underlying: Bio-Rad A Common Stock · 30 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 122 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 41 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · derivative · entry 12 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126 Underlying: Bio-Rad A Common Stock · 41 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 167 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 167 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
GrantRestricted Stock Units · Derivative | 298 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · derivative · entry 11 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298 Underlying: Bio-Rad A Common Stock · 298 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Tax withholdingBio-Rad A Common Stock | 12 | $394.60 | $4,735.20 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 4 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,069 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Exercise / conversionBio-Rad A Common Stock | 30 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 3 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Tax withholdingBio-Rad A Common Stock | 17 | $394.60 | $6,708.20 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 2 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,051 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:58 UTC |
Allison SchwartzDirector
|
Exercise / conversionBio-Rad A Common Stock | 41 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017642 · form4.xml · nonDerivative · entry 1 Allison Schwartz · CIK 0001924980 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Exercise / conversionRestricted Stock Units · Derivative | 371 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 13 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 744 Underlying: Bio-Rad A Common Stock · 371 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,486 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Exercise / conversionRestricted Stock Units · Derivative | 520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 12 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562 Underlying: Bio-Rad A Common Stock · 520 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
GrantRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · derivative · entry 11 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,005 Underlying: Bio-Rad A Common Stock · 3,005 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Tax withholdingBio-Rad A Common Stock | 129 | $394.60 | $50,903.40 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 4 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,188.9894 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Exercise / conversionBio-Rad A Common Stock | 371 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 3 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,317.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Tax withholdingBio-Rad A Common Stock | 180 | $394.60 | $71,028.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 2 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,946.9894 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:55 UTC |
MAY SIMONEVP, President, LSG
|
Exercise / conversionBio-Rad A Common Stock | 520 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017638 · form4.xml · nonDerivative · entry 1 MAY SIMON · CIK 0001900904 · EVP, President, LSG 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,126.9894 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 32.1340 and 24.5800 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2023 and 06/30/2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Exercise / conversionRestricted Stock Units · Derivative | 329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · derivative · entry 12 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 659 Underlying: Bio-Rad A Common Stock · 329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Exercise / conversionRestricted Stock Units · Derivative | 520 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · derivative · entry 11 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,562 Underlying: Bio-Rad A Common Stock · 520 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 2,082 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Tax withholdingBio-Rad A Common Stock | 114 | $394.60 | $44,984.40 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · nonDerivative · entry 4 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,996.0277 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Exercise / conversionBio-Rad A Common Stock | 329 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · nonDerivative · entry 3 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,110.0277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Tax withholdingBio-Rad A Common Stock | 180 | $394.60 | $71,028.00 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · nonDerivative · entry 2 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,781.0277 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:56 UTC |
Dahowski DianeEVP, Global Supply Chain
|
Exercise / conversionBio-Rad A Common Stock | 520 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017640 · form4.xml · nonDerivative · entry 1 Dahowski Diane · CIK 0001926636 · EVP, Global Supply Chain 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,961.0277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 31.8970 and 24.7960 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 03/31/2023 and 06/30/2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 253 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · derivative · entry 13 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507 Underlying: Bio-Rad A Common Stock · 253 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,013 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Exercise / conversionRestricted Stock Units · Derivative | 347 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · derivative · entry 12 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,041 Underlying: Bio-Rad A Common Stock · 347 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 1,388 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
GrantRestricted Stock Units · Derivative | 2,003 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · derivative · entry 11 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,003 Underlying: Bio-Rad A Common Stock · 2,003 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Tax withholdingBio-Rad A Common Stock | 88 | $394.60 | $34,724.80 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · nonDerivative · entry 4 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,272 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Exercise / conversionBio-Rad A Common Stock | 253 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · nonDerivative · entry 3 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,360 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Tax withholdingBio-Rad A Common Stock | 120 | $394.60 | $47,352.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · nonDerivative · entry 2 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,107 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:52 UTC |
COREY COLLEENEVP, Global Human Resources
|
Exercise / conversionBio-Rad A Common Stock | 347 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017636 · form4.xml · nonDerivative · entry 1 COREY COLLEEN · CIK 0001976271 · EVP, Global Human Resources 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 16:50 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
GrantRestricted Stock Units · Derivative | 12,020 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017634 · form4.xml · derivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,020 Underlying: Bio-Rad A Common Stock · 12,020 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 18:00 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,350 | $0.00 Strike: $215.98 | $0.00 |
DisclosureSEC source: 0001062993-23-017340 · form4.xml · derivative · entry 5 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,350 shares Expires 2027-09-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 2,500 shares, became exercisable in five equal annual installments beginning on September 5, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 18:00 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 377 | $396.44 | $149,457.88 |
DisclosureSEC source: 0001062993-23-017340 · form4.xml · nonDerivative · entry 4 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,415.7965 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $396.09 to $396.53, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 18:00 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 1,582 | $395.76 | $626,092.32 |
DisclosureSEC source: 0001062993-23-017340 · form4.xml · nonDerivative · entry 3 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,792.7965 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $395.07 to $395.95, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 18:00 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
SaleBio-Rad A Common Stock | 391 | $394.16 | $154,116.56 |
DisclosureSEC source: 0001062993-23-017340 · form4.xml · nonDerivative · entry 2 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,374.7965 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $394.01 to $394.95, inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 30, 2023 Filed Aug 31, 2023 18:00 UTC |
ERNST TIMOTHY SEVP, General Counsel & Sec
|
Exercise / conversionBio-Rad A Common Stock | 2,350 | $215.98 | $507,553.00 |
DisclosureSEC source: 0001062993-23-017340 · form4.xml · nonDerivative · entry 1 ERNST TIMOTHY S · CIK 0001676291 · EVP, General Counsel & Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,765.7965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $117.50 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 20 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad B Common Stock · 39,000 shares Expires 2023-09-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option, representing a right to purchase a total of 39,000 shares, became exercisable in five equal annual installments beginning on September 11, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 2,600 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 19 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Bio-Rad A Common Stock · 2,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F9 · derivative.exercise_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments, of which 2,600 vested on August 25, 2023. F9 · derivative.expiration_date: On September 4, 2018, the reporting person was granted 13,000 restricted stock units, vesting in five equal annual installments, of which 2,600 vested on August 25, 2023. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 2,320 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 18 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,320 Underlying: Bio-Rad A Common Stock · 2,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F8 · derivative.exercise_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments, of which 2,320 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F8 · derivative.expiration_date: On September 3, 2019, the reporting person was granted 11,597 restricted stock units, vesting in five equal annual installments, of which 2,320 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 1,805 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 17 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,805 Underlying: Bio-Rad A Common Stock · 1,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments, of which 1,805 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 7,220 restricted stock units, vesting in four equal annual installments, of which 1,805 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 1,266 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 16 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,532 Underlying: Bio-Rad A Common Stock · 1,266 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments, of which 1,266 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 5,064 restricted stock units, vesting in four equal annual installments, of which 1,266 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionRestricted Stock Units · Derivative | 2,081 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · derivative · entry 15 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,245 Underlying: Bio-Rad A Common Stock · 2,081 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments, of which 2,081 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments, of which 2,081 vested on August 25, 2023. The remaining restricted stock units will vest on the yearly anniversary date of the grant. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad B Common Stock | 25,389 | $381.78 | $9,693,012.42 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 12 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,300 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad B Common Stock | 39,000 | $117.50 | $4,582,500.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 11 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad A Common Stock | 1,290 | $381.78 | $492,496.20 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 10 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,920 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad A Common Stock | 2,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 9 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 434,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad A Common Stock | 1,151 | $381.78 | $439,428.78 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 8 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,610 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad A Common Stock | 2,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 7 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 432,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad A Common Stock | 895 | $381.78 | $341,693.10 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 6 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 430,441 Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Exercise / conversionBio-Rad A Common Stock | 1,805 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 5 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 431,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 17:29 UTC |
SCHWARTZ NORMAN DDirector · Chairman, President, and CEO · 10% owner
|
Tax withholdingBio-Rad A Common Stock | 628 | $381.78 | $239,757.84 |
DisclosureSEC source: 0001062993-23-017146 · form4.xml · nonDerivative · entry 4 SCHWARTZ NORMAN D · CIK 0000940805 · Director · Chairman, President, and CEO · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 429,531 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.